Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$0.25
$0.36
$0.21
▼
$3.18
$3.69M1.2669,218 shs3.60 million shs
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
$0.08
$0.08
$0.04
▼
$0.12
$13.90M-0.772,759 shsN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.20
$0.73
$0.54
▼
$1.87
$14.70M0.5480,200 shs300,801 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$0.86
$1.17
$0.84
▼
$12.23
$13.68M-1.72188,255 shs69,028 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.00%+1.85%-9.43%-50.79%-91.03%
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
0.00%-7.73%+1.14%-11.11%+53.85%
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00%+79.17%+71.18%+98.35%-18.92%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
0.00%-7.52%-21.44%-58.02%-88.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$0.25
$0.36
$0.21
▼
$3.18
$3.69M1.2669,218 shs3.60 million shs
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
$0.08
$0.08
$0.04
▼
$0.12
$13.90M-0.772,759 shsN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.20
$0.73
$0.54
▼
$1.87
$14.70M0.5480,200 shs300,801 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$0.86
$1.17
$0.84
▼
$12.23
$13.68M-1.72188,255 shs69,028 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.00%+1.85%-9.43%-50.79%-91.03%
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
0.00%-7.73%+1.14%-11.11%+53.85%
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00%+79.17%+71.18%+98.35%-18.92%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
0.00%-7.52%-21.44%-58.02%-88.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
3.00
Buy$9.003,448.90% Upside
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
0.00
N/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
1.00
SellN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest AIM, TPST, SYBX, and INTI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/13/2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/1/2026
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$10.00 ➝ $9.00
5/14/2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$90K41.03N/AN/A($2.99) per share-0.08
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
N/AN/AN/AN/A($0.01) per shareN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
$8K1,837.35N/AN/A$1.09 per share1.10
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A$1.35 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-$13.96M-$24.68N/AN/AN/A-14,123.40%N/A-177.72%N/A
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
-$3.30M-$0.01N/AN/AN/AN/A-1,693.49%-122.07%N/A
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$0.06N/AN/AN/AN/A-26.47%-18.00%N/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$26.26M-$6.01N/AN/AN/AN/A-355.61%-121.21%8/10/2026 (Estimated)

Latest AIM, TPST, SYBX, and INTI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$0.30N/AN/AN/AN/AN/A
5/15/2026Q1 2026
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/A-$0.69N/A-$0.69N/A$0.02 million
5/14/2026Q1 2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$0.28-$2.53-$2.25-$2.53N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/AN/A
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.10
1.01
1.01
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
N/A
3.60
3.60
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
2.65
2.65
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
0.74
0.74

Institutional Ownership

CompanyInstitutional Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
12.02%
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
N/A
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%

Insider Ownership

CompanyInsider Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.95%
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
4.60%
Synlogic, Inc. stock logo
SYBX
Synlogic
2.62%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
36.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
2014.56 million14.43 millionNot Optionable
Inhibitor Therapeutics, Inc. stock logo
INTI
Inhibitor Therapeutics
1173.79 million165.80 millionNot Optionable
Synlogic, Inc. stock logo
SYBX
Synlogic
8012.25 million11.39 millionNo Data
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
2015.98 million10.20 millionNo Data

Recent News About These Companies

Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69081647-tempest-therapeutics-tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-399.htm
Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases
July 21, 2026  |  quiverquant.comQ
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330290/0/en/tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-t.html
Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial
July 15, 2026  |  quiverquant.comQ
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
July 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/15/3327582/0/en/tempest-unveils-next-generation-in-vivo-car-t-pipeline-with-first-clinical-study-planned-for-the-fourth-quarter-of-2026.html
Tempest Therapeutics, Inc. Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026  |  quiverquant.comQ
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3307117/0/en/tempest-therapeutics-appoints-drake-richey-and-john-yee-md-mph-to-board-of-directors.html
Tempest Therapeutics Announces Resignation of Board Director
May 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tempest-therapeutics-announces-resignation-of-board-director?utm_source=marketbeat.com&utm_medium=referral
Tempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term Warrants
May 29, 2026  |  quiverquant.comQ
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
May 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/29/3303540/0/en/tempest-therapeutics-announces-warrant-exercise-for-approximately-2-million-in-gross-proceeds.html
Tempest Therapeutics Announces Multiple Board Director Resignations
May 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tempest-therapeutics-announces-multiple-board-director-resignations?utm_source=marketbeat.com&utm_medium=referral
Tempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68505685-tempest-therapeutics-tempest-reports-first-quarter-2026-financial-results-and-provides-business-update-399.htm
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3295395/0/en/tempest-reports-first-quarter-2026-financial-results-and-provides-business-update.html
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288654/0/en/tempest-presents-clinical-update-at-isct-2026-annual-meeting.html
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283678/0/en/tempest-to-advance-dual-targeting-car-t-platform-with-clinical-update-at-isct-2026-annual-meeting.html
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3278911/0/en/tempest-announces-key-manufacturing-milestone-for-tpst-2003-dual-targeting-cd19-bcma-car-t.html
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
April 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/14/3273302/0/en/tempest-appoints-andrew-fang-ph-d-as-head-of-business-development-to-advance-strategic-partnerships-and-global-licensing-efforts.html
New Strong Buy Stocks for April 10th
April 10, 2026  |  zacks.comhttps://www.zacks.com/commentary/2897019/new-strong-buy-stocks-for-april-10th
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST)
April 1, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/1088664/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-and-tempest-therapeutics-tpst/
Tempest Reports Year End 2025 Financial Results and Provides Business Update
March 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/30/3264681/0/en/tempest-reports-year-end-2025-financial-results-and-provides-business-update.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Delta Air Lines logo displayed over a close-up of the airline's aircraft fuselage, tail, and engine against a blue sky.
Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
By Thomas Hughes | July 12, 2026
Microsoft logo surrounded by a glowing digital network graphic in a data center with screens displaying charts and code.
Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
By Chris Markoch | July 12, 2026
AMD and Cerebras logos connected by glowing cables between server hardware racks in a data center.
AMD and Cerebras Create A New Blueprint For Hardware
By Jeffrey Neal Johnson | July 24, 2026
An easyJet passenger jet with orange livery and logo flying above clouds against a blue sky.
Baggage Claim: Apollo’s $7.7 Billion Bid to Acquire easyJet
By Jeffrey Neal Johnson | July 14, 2026
Technicians in AST SpaceMobile gear prepare a satellite and payload fairing in a hangar as a rocket stands on the launch pad outside.
Is Buying a Launch Company AST SpaceMobile’s Next Vertical Integration Move?
By Jessica Mitacek | July 23, 2026
AIM ImmunoTech stock logo

AIM ImmunoTech NYSEAMERICAN:AIM

$0.25 0.00 (0.00%)
Closing price 07/31/2026 04:10 PM Eastern
Extended Trading
$0.26 +0.01 (+2.13%)
As of 07/31/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Inhibitor Therapeutics stock logo

Inhibitor Therapeutics OTCMKTS:INTI

$0.08 0.00 (0.00%)
As of 07/31/2026

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.20 0.00 (0.00%)
As of 07/31/2026 03:56 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$0.86 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$0.86 +0.00 (+0.20%)
As of 07/31/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas